GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: P005672 | Seysara®
                                 
                                                         
                            
                            
                            
                                 
                                
                                sarecycline is an approved drug (FDA (2018)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Sarecycline is a tetracycline antibacterial with narrow-spectrum activity that was developed as an oral anti-acne therapeutic. Note that the structure shown here matches the CAS-assigned structure and is the same as the ChEMBL entry linked to below. The PubChem standardized chemical structure (CID 54681908) for sarecycline is represented with slightly different stereochemistry.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| Sarecycline is indicated for the treatment of moderate to severe cases of inflammatory lesions of non-nodular acne vulgaris. Sarecycline hydrochloride, as an oral formulation under the trade name Seysara®, was granted first approval by the US FDA in October 2018 [1]. | 
Mechanism Of Action and Pharmacodynamic Effects ![]()  | 
                                                        
| Sarecycline inhibits protein synthesis in the bacterial ribosome and has been shown to bind to two active sites on the 70S ribosome of Cutibacterium acnes [2]. | 
External links ![]()  | 
                                                            
| 
                                                                    For extended ADME data see the following: Drugs.com  |